Literature DB >> 12769781

Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents.

S Theocharisa1, A Margeli, G Kouraklis.   

Abstract

The Peroxisome Proliferator Activated Receptors (PPARs) are initially described as molecular targets for compounds inducing peroxisome proliferation. Among the three PPAR subtypes (alpha, beta, gamma), PPAR-gamma acting as a ligand-activated transcription factor, proved to be an important regulator of adipogenic differentiation and glucose homeostasis. Recent data support evidence for participation of PPAR-gamma, upon ligands activation, in the biological mechanisms underlying the carcinogenic evolution. Specific PPAR-gamma ligands affect cancer cells proliferation and differentiation acting as cell cycle modulators, suggesting their use as an important tool for future therapeutic approach in cancer. In this review, the latest knowledge on PPAR-gamma activation and molecular mechanisms of PPAR-gamma ligands mediated anti-tumoral activity are presented. In vitro and in vivo studies concerning the use of PPAR-gamma ligands in different cancer types are also included.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769781     DOI: 10.2174/1568011033482431

Source DB:  PubMed          Journal:  Curr Med Chem Anticancer Agents        ISSN: 1568-0118


  8 in total

1.  Pioglitazone treatment in Cushing's disease.

Authors:  D Barbaro; P Lapi; P Orsini; C Pasquini; S Ciaccio
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Anti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation.

Authors:  Ki Young Kim; Jin Hee Ahn; Hyae Gyeong Cheon
Journal:  Mol Cell Biochem       Date:  2011-07-17       Impact factor: 3.396

3.  Effect of miR-340 on gastric cancer cell proliferation and apoptosis.

Authors:  Xu Hou; Haiquan Qiao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  In Vivo RNAi Screen Unveils PPARγ as a Regulator of Hematopoietic Stem Cell Homeostasis.

Authors:  Mathieu Sertorio; Wei Du; Surya Amarachintha; Andrew Wilson; Qishen Pang
Journal:  Stem Cell Reports       Date:  2017-04-13       Impact factor: 7.765

Review 5.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

6.  Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer.

Authors:  Costas Giaginis; Anna Tsantili-Kakoulidou; Stamatios Theocharis
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

7.  Pioglitazone Effect on Glioma Stem Cell Lines: Really a Promising Drug Therapy for Glioblastoma?

Authors:  Chiara Cilibrasi; Valentina Butta; Gabriele Riva; Angela Bentivegna
Journal:  PPAR Res       Date:  2016-05-25       Impact factor: 4.964

8.  miR‑127 aggravates myocardial failure by promoting the TGF‑β1/Smad3 signaling.

Authors:  Hainian Xu; Fengmei Li
Journal:  Mol Med Rep       Date:  2018-09-27       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.